Related Experiment Video
Updated: Oct 17, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Beta3-Adrenergic Receptor Activation Alleviates Cardiac Dysfunction in Cardiac Hypertrophy by Regulating Oxidative
Mingming Zhang1, Yuerong Xu2, Jianghong Chen1
1Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Background:
Excessive myocardial oxidative stress could lead to the congestive heart failure. NADPH oxidase is involved in the pathological process of left ventricular (LV) remodeling and dysfunction. β3-Adrenergic receptor (AR) could regulate cardiac dysfunction proved by recent researches. The molecular mechanism of β3-AR regulating oxidative stress, especially NADPH oxidase, remains to be determined.
Methods:
Cardiac hypertrophy was constructed by the transverse aortic constriction (TAC) model. ROS and NADPH oxidase subunits expression were assessed after β3-AR agonist (BRL) or inhibitor (SR) administration in cardiac hypertrophy. Moreover, the cardiac function, fibrosis, heart size, oxidative stress, and cardiomyocytes apoptosis were also detected.
Results:
β3-AR activation significantly alleviated cardiac hypertrophy and remodeling in pressure-overloaded mice. β3-AR stimulation also improved heart function and reduced cardiomyocytes apoptosis, oxidative stress, and fibrosis. Meanwhile, β3-AR stimulation inhibited superoxide anion production and decreased NADPH oxidase activity. Furthermore, BRL treatment increased the neuronal NOS (nNOS) expression in cardiac hypertrophy.
Conclusion:
β3-AR stimulation alleviated cardiac dysfunction and reduced cardiomyocytes apoptosis, oxidative stress, and fibrosis by inhibiting NADPH oxidases. In addition, the protective effect of β3-AR is largely attributed to nNOS activation in cardiac hypertrophy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure II: Pathophysiology
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

